Immune-Mediated Hemolytic Anemia in Dogs and Cats: Signs, Treatment and Prognosis

Immune-Mediated Hemolytic Anemia in Dogs and Cats: Signs, Treatment and Prognosis

By Dr Duncan Houston

Immune-mediated hemolytic anemia, usually shortened to IMHA, is one of the most serious causes of anemia in dogs. It can also affect cats, although it is diagnosed less commonly in this species.

IMHA occurs when the immune system mistakenly targets red blood cells for destruction. The resulting anemia can worsen quickly, leaving the body unable to deliver enough oxygen to vital organs. In dogs, abnormal blood clot formation is another major concern and can be just as dangerous as the anemia itself. (OUP Academic)

Early recognition, hospitalization, careful diagnostic testing, blood transfusion when needed, and rapid treatment can give an affected animal a realistic chance of recovery.

Quick Answer

Suspected IMHA requires urgent veterinary assessment. Pale or yellow gums, severe weakness, rapid breathing, dark orange or brown urine, collapse, or sudden deterioration should be treated as an emergency.

IMHA cannot be diagnosed from one blood test alone. Diagnosis requires evidence of anemia, red blood cell destruction, and an immune-mediated process. Treatment may include blood transfusions, immunosuppressive medication, treatment of any underlying trigger, and clot prevention in most affected dogs. (OUP Academic)

What Is Immune-Mediated Hemolytic Anemia?

Red blood cells carry oxygen from the lungs to the rest of the body. In IMHA, antibodies, complement proteins, or both attach to the surface of these cells and mark them for destruction.

Red blood cells may then be:

• Removed from circulation by the spleen and liver, known as extravascular hemolysis

• Destroyed directly within the bloodstream, known as intravascular hemolysis

• Partially damaged, producing smaller and more densely stained cells called spherocytes in dogs

The breakdown of red blood cells releases bilirubin and sometimes free hemoglobin. This can cause yellow gums, yellow skin, yellowing of the whites of the eyes, orange or brown urine, and discoloured blood plasma. (OUP Academic)

IMHA may be classified as:

• Non-associative IMHA: No underlying trigger is identified

• Associative IMHA: The immune destruction occurs alongside a potentially related infection, inflammatory disease, cancer, drug exposure, toxin, or another medical condition

The term “primary IMHA” is still widely used, but “non-associative IMHA” is often more accurate because it acknowledges that an unidentified trigger may still exist. (OUP Academic)

How Serious Is IMHA?

There is no genuinely low-risk form of confirmed IMHA. Some patients are more stable than others, but even an animal that is still walking and eating can deteriorate as red blood cells continue to be destroyed.

Risk level	What it may look like	What to do
Suspected but currently stable	Mild lethargy, reduced exercise tolerance, subtle gum pallor, an unexpected low red blood cell count	Arrange an urgent same-day veterinary examination
High risk	Clearly pale or yellow gums, dark urine, rapid breathing, marked weakness, poor appetite, fever, rapidly falling PCV or hematocrit	Emergency assessment and likely hospitalization
Critical	Collapse, inability to stand, severe breathing difficulty, altered awareness, profound weakness, sudden neurological signs, or evidence of major bleeding	Immediate emergency treatment and stabilization

Do not wait for collapse before seeking help. By the time an animal can no longer stand, oxygen delivery may already be severely compromised.

Signs of IMHA in Dogs and Cats

Signs vary depending on how quickly the anemia develops and whether complications such as thrombosis are present.

Common signs include:

• Pale, white, cream, or yellow gums

• Weakness and lethargy

• Reduced exercise tolerance

• Rapid breathing, particularly while resting

• Rapid heart rate

• Reduced appetite

• Vomiting

• Fever

• Orange, red, tea-coloured, or brown urine

• Yellow skin or eyes

• Collapse

• Sudden deterioration after appearing mildly unwell

Some patients develop severe anemia without obvious jaundice or dark urine. The absence of these signs does not rule out IMHA. Some dogs and cats may also have nonregenerative anemia when first examined because the bone marrow has not yet had time to produce and release enough replacement red blood cells. (OUP Academic)

When Is IMHA an Emergency?

Seek emergency veterinary treatment immediately if your dog or cat has:

• Very pale, white, grey, or yellow gums

• Rapid or laboured breathing

• Collapse or an inability to stand

• Severe weakness that is worsening over hours

• Orange, red, or brown urine

• Sudden confusion, seizures, loss of balance, or other neurological signs

• A swollen or painful limb

• Abdominal distension or evidence of internal bleeding

• Black stools, vomiting blood, bruising, or pinpoint red spots on the skin

• A known diagnosis of IMHA with any sudden deterioration

Sudden breathing difficulty, collapse, neurological changes, or limb pain may indicate thromboembolism. In dogs, thrombosis is one of the most important causes of complications and death associated with IMHA. (OUP Academic)

What Causes IMHA?

In many dogs, no definitive underlying cause is found. These patients are classified as having non-associative IMHA.

Potential associations include:

• Vector-borne infections, particularly some Babesia species

• Other infectious diseases

• Cancer

• Pancreatitis or other inflammatory diseases

• Certain drugs or toxins

• Previous blood transfusion

• Severe tissue injury or inflammation

• Another immune-mediated disease

The strength of evidence differs considerably between suspected triggers. Finding another abnormality does not automatically prove that it caused the IMHA. The work-up should therefore be guided by the patient’s age, history, examination findings, geographic location, travel history, parasite exposure, medications, and laboratory results. (OUP Academic)

Possible causes in cats

Important conditions to investigate in cats include:

• Mycoplasma haemofelis and other feline hemoplasmas

• Feline leukemia virus

• Feline infectious peritonitis when the wider clinical picture supports it

• Cancer

• Inflammatory disease

• Drug or toxin exposure

• Previous blood transfusion

Many cats still have no identifiable underlying trigger after appropriate investigation. (PubMed Central (PMC))

Can vaccination trigger IMHA?

Vaccination requires balanced wording.

A multicentre study published in April 2026 found that dogs with IMHA were more likely than matched control dogs to have received a vaccine during the preceding 30 days. However, the researchers specifically concluded that this represented a possible temporal association and did not establish that vaccination caused IMHA. Only a small proportion of affected dogs had been vaccinated during that period. (OUP Academic)

A recent vaccine should therefore be recorded in the clinical history and a suspected adverse reaction should be reported appropriately. It should not automatically be declared the cause, and owners should not stop all future vaccination without an individual risk assessment involving their veterinarian.

Are Dogs and Cats Affected in the Same Way?

There are important species differences.

Feature	Dogs	Cats
How commonly it is recognised	Relatively common immune-mediated disease	Uncommon but potentially severe
Spherocytes	Moderate or marked spherocytosis can support the diagnosis	Spherocytes are difficult to recognise reliably and should not be used in the same way
Bone marrow response	May initially be regenerative or nonregenerative	Nonregenerative presentations are also possible
Thrombosis	Major recognised complication, with thromboprophylaxis recommended for most dogs	Thrombotic risk and treatment must be assessed individually
Evidence for treatment protocols	Stronger consensus guidance is available	Evidence is more limited and treatment should not simply copy canine protocols

A feline case should not be assessed as though it were merely a smaller canine case. The diagnostic evidence, infectious disease testing, medication choices, and clotting risk all require species-specific consideration. (OUP Academic)

What Else Can Look Like IMHA?

Not every anemia is IMHA, and not every hemolytic anemia is immune-mediated.

Important alternatives include:

• Active bleeding from trauma, surgery, gastrointestinal disease, parasites, a bleeding tumour, or a clotting disorder

• Oxidative damage from zinc, onions, garlic, acetaminophen, or other toxins

• Infectious destruction of red blood cells

• An acute transfusion reaction

• Red blood cell fragmentation caused by vascular disease or disseminated intravascular coagulation

• Inherited red blood cell disorders

• Hypophosphatemia

• Bone marrow disease

• Severe chronic inflammatory disease

• Kidney disease or other causes of reduced red blood cell production

Spherocytes can occasionally occur with conditions other than IMHA, including oxidative injury and some vascular disorders. This is another reason a blood smear finding should not be interpreted in isolation. (OUP Academic)

How Do Veterinarians Diagnose IMHA?

There is no single gold-standard test for IMHA. Diagnosis is built from several pieces of evidence.

1. Confirming anemia

A complete blood count, packed cell volume, hematocrit, reticulocyte count, and blood smear help determine:

• How severe the anemia is

• Whether the bone marrow is responding

• Whether platelets are also reduced

• Whether spherocytes, autoagglutination, ghost cells, parasites, oxidative changes, or fragmented cells are present

A lack of reticulocytes at presentation does not exclude IMHA. The marrow response can lag behind the destruction of circulating red blood cells. (OUP Academic)

2. Finding evidence of hemolysis

Evidence that red blood cells are being destroyed may include:

• Increased bilirubin

• Jaundice

• Bilirubin in the urine

• Hemoglobin in the blood plasma

• Hemoglobin in the urine

• Ghost cells on a fresh blood smear

• A falling packed cell volume without evidence of bleeding

Dark urine alone does not prove hemolysis because blood, muscle pigment, concentrated urine, and urinary disease can create similar colour changes.

3. Finding evidence of immune-mediated destruction

Tests may include:

• Saline agglutination testing

• Direct antiglobulin testing, commonly called a Coombs test

• Flow cytometry

• Assessment for spherocytes in dogs

A positive direct antiglobulin test supports immune attachment to red blood cells, but false-positive and false-negative results occur. It does not confirm IMHA by itself.

The ACVIM diagnostic consensus recommends combining anemia with evidence of hemolysis and more than one marker of immune-mediated red blood cell destruction, unless persistent agglutination remains present after appropriate saline washing. (OUP Academic)

4. Searching for an underlying trigger

Testing may include:

• Medication, toxin, transfusion, travel, parasite, and vaccination history

• Blood chemistry

• Urinalysis

• Infectious disease testing selected for the region and exposure history

• Thoracic or abdominal imaging

• Additional tests based on the animal’s age and clinical findings

Not every patient requires every available test. A 2026 study of 117 dogs found that diagnostic imaging did not alter survival odds in dogs classified as having non-associative IMHA, supporting a more individualised approach rather than automatic one-size-fits-all screening. Imaging remains important when age, examination findings, laboratory abnormalities, or symptoms create concern for cancer or another underlying condition. (Wiley Online Library)

5. Assessing severity and complications

Veterinarians may monitor:

• Heart rate and respiratory rate

• Blood pressure

• Oxygen delivery

• Lactate

• Platelet count

• Kidney and liver values

• Coagulation results

• Evidence of thrombosis

• The rate at which the packed cell volume is falling

Lactate can help assess poor tissue perfusion and response to stabilization. It is not an IMHA diagnostic test. A single admission value has limited prognostic accuracy, while persistent hyperlactatemia after treatment is more concerning than an initially high value that improves. (PubMed)

How Is IMHA Treated?

Treatment depends on the species, severity of anemia, rate of red blood cell destruction, clotting risk, and whether an underlying cause has been identified.

Blood transfusion

Packed red blood cells are commonly used when anemia is causing inadequate oxygen delivery.

The decision should not be based on one fixed packed cell volume or hematocrit threshold. Veterinarians also consider:

• Weakness and mental state

• Heart rate and breathing effort

• Lactate and perfusion

• Speed of red blood cell loss

• Other diseases affecting oxygen delivery

The immune system may eventually destroy some transfused cells, but this is not a reason to withhold a necessary transfusion. Donor cells can provide lifesaving oxygen-carrying capacity while immunosuppressive treatment begins to control the disease. (OUP Academic)

Immunosuppressive treatment

Glucocorticoids such as prednisone or prednisolone are the main first-line treatment for canine IMHA. Intravenous dexamethasone may be used temporarily when an animal cannot tolerate oral medication.

A second immunosuppressive medication may be considered when:

• Disease is particularly severe

• Red blood cell destruction continues

• The response to glucocorticoids is inadequate

• Steroid-related adverse effects are becoming difficult to manage

• A lower long-term steroid dose is needed

Options in dogs may include cyclosporine, mycophenolate, or azathioprine. No second medication has been shown to be universally superior for every patient, and medication selection must account for species, concurrent disease, adverse-effect risk, and monitoring requirements. (Wiley Online Library)

Preventing blood clots in dogs

Most dogs diagnosed with IMHA should receive thromboprophylaxis unless severe thrombocytopenia or another major bleeding risk makes it unsafe.

Current canine consensus guidance recommends:

• Starting thromboprophylaxis at diagnosis

• Giving particular attention to the first two weeks, when thrombotic and mortality risk are highest

• Preferentially using an anticoagulant-based strategy during the early high-risk period when feasible

• Using clopidogrel in preference to aspirin when an antiplatelet drug is selected

The best protocol varies between patients, and several commonly used medications require dose adjustment or monitoring. Owners should never begin aspirin, clopidogrel, heparin, rivaroxaban, or another antithrombotic medication without direct veterinary instruction. (OUP Academic)

Treating an underlying cause

When a relevant trigger is found, treating it may reduce continued immune stimulation.

This may involve:

• Antimicrobial treatment for a confirmed infection

• Appropriate parasite treatment

• Discontinuing a suspected medication

• Removing a toxin source

• Treating inflammatory disease

• Investigating and treating cancer

• Managing another concurrent immune-mediated disease

Antibiotics should not be given automatically unless there is a reasonable infectious indication.

Supportive care

Depending on the patient, supportive treatment may include:

• Oxygen

• Careful fluid therapy

• Antiemetic medication

• Nutritional support

• Pain relief when appropriate

• Management of electrolyte abnormalities

• Monitoring for kidney, liver, respiratory, neurological, or clotting complications

Gastroprotective medication is not automatically required in every patient. It is most appropriate when there is evidence of gastrointestinal bleeding, ulceration, or a meaningful risk of these complications. (OUP Academic)

What Is Evans Syndrome?

Evans syndrome refers to immune-mediated destruction of both:

• Red blood cells, causing IMHA

• Platelets, causing immune thrombocytopenia

The two conditions may develop at the same time or sequentially.

Affected animals may have anemia together with bruising, pinpoint skin haemorrhages, nosebleeds, gastrointestinal bleeding, or very low platelet counts. Evans syndrome increases bleeding risk and makes decisions about thromboprophylaxis more complicated.

It does not mean that the animal has no ability to form blood clots. Dogs with IMHA can remain at risk of thrombosis even when their platelet count is reduced, so treatment must balance bleeding risk against clotting risk. (Wiley Online Library)

What Is the Prognosis for IMHA?

The prognosis is guarded, but IMHA is not automatically hopeless.

Outcome depends on:

• How quickly treatment begins

• The severity and speed of the anemia

• Whether transfusions restore adequate oxygen delivery

• Whether red blood cell destruction can be controlled

• Development of thrombosis

• Platelet count

• Bilirubin and lactate trends

• Organ dysfunction

• The presence of an underlying infection, cancer, or inflammatory disease

• Relapse during or after treatment

In a 2025 study of 206 dogs with non-associative IMHA, 80% were alive at hospital discharge, 70% were alive at one month, and 55% were alive at six months. Other published populations have reported first-month mortality of approximately 18% to 44%, which demonstrates how much outcome varies between studies and individual patients. (OUP Academic)

The first two weeks of treatment are generally the most dangerous. A patient that survives the initial crisis, maintains a stable red blood cell count, avoids thrombosis, and responds to immunosuppression has a much better long-term outlook. (OUP Academic)

Prognosis in cats

Feline prognosis depends heavily on whether another serious disease is present.

In a retrospective study of 107 cats, those classified as having primary or non-associative IMHA had a median survival of 516 days, compared with 14 days in cats with secondary IMHA. At six months, 59.3% of cats with primary IMHA were alive compared with 25.8% of cats with secondary disease. These figures describe one historical referral population and should not be treated as a prediction for every individual cat. (PubMed Central (PMC))

How Long Does Treatment Last?

Treatment usually continues for months rather than days.

For dogs responding appropriately, ACVIM guidance recommends considering the first glucocorticoid reduction only after the packed cell volume or hematocrit has remained stable above 30% for approximately two weeks and other signs of disease activity are improving.

A typical treatment course may involve:

• Prednisone or prednisolone for approximately three to six months

• Total immunosuppressive treatment lasting approximately four to eight months

• Packed cell volume or hematocrit checks every one to three weeks during active treatment and tapering

• Periodic monitoring of bilirubin, reticulocytes, agglutination, blood smear findings, and medication adverse effects

These are general expectations, not a rigid schedule. Medication must be adjusted according to the individual patient’s response. (OUP Academic)

Can IMHA Relapse?

Yes. Relapse can occur during medication tapering, after treatment has ended, or following a new inflammatory or infectious event.

Reported relapse estimates vary between studies, with figures commonly falling around 11% to 24%. A suspected relapse should be confirmed rather than assumed because blood loss, infection, medication complications, bone marrow suppression, and other diseases can also cause a falling red blood cell count. (OUP Academic)

Signs that may indicate relapse include:

• Returning lethargy

• Pale or yellow gums

• Dark urine

• Reduced appetite

• Faster breathing

• Weakness

• A falling packed cell volume or hematocrit

Never reduce or stop immunosuppressive medication simply because the animal appears brighter at home.

What Should You Do Right Now?

When IMHA is suspected

1. Arrange urgent veterinary assessment today. Collapse, severe weakness, breathing difficulty, or white gums require an emergency hospital immediately.

2. Keep your pet calm and restrict exercise. Physical exertion increases oxygen demand.

3. Carry or support a severely weak animal when this can be done safely.

4. Bring a complete history. Include medications, supplements, possible toxins, travel, tick exposure, previous transfusions, recent illnesses, and vaccination dates.

5. Bring previous blood results if another clinic has already performed testing.

6. Do not give aspirin, iron, steroids, human pain medication, or leftover prescriptions unless a veterinarian specifically directs you to do so.

When IMHA has already been diagnosed

• Give every medication exactly as prescribed

• Do not miss or suddenly stop steroid doses

• Attend all scheduled blood checks

• Monitor gum colour, breathing rate, urine colour, appetite, energy, vomiting, stool colour, and bruising

• Contact the treating clinic if medication adverse effects become difficult to manage

• Return immediately if weakness, pallor, jaundice, dark urine, collapse, breathing difficulty, or neurological signs develop

Common Mistakes With IMHA

Waiting to see whether pale gums improve

Pale gums with lethargy or rapid breathing are not appropriate for home monitoring. Severe anemia can deteriorate over hours.

Assuming dark urine is only dehydration or a urinary infection

Orange, red, or brown urine may represent bilirubin or free hemoglobin from red blood cell destruction.

Treating a positive Coombs test as definitive proof

A direct antiglobulin test is one part of the diagnostic picture. It must be interpreted alongside anemia, hemolysis, blood smear findings, and other immune-mediated markers.

Avoiding a necessary transfusion because the new cells may be destroyed

Transfusions do not cure IMHA, but they can maintain oxygen delivery while disease-directed treatment begins working.

Giving aspirin at home

Aspirin is not harmless. It may worsen gastrointestinal bleeding, interact with glucocorticoids, and may be the wrong antithrombotic strategy for the patient.

Reducing medication too quickly

A brighter attitude does not prove that the immune destruction has stopped. Tapering should follow repeat blood tests and other markers of disease activity.

Assuming a recent vaccine proves causation

A temporal relationship should be documented and investigated, but current evidence does not establish that vaccination directly caused an individual case.

Can IMHA Be Prevented?

Most cases of non-associative IMHA cannot currently be prevented.

Practical risk reduction includes:

• Maintaining appropriate parasite prevention

• Discussing travel-related infectious disease risks

• Preventing access to zinc-containing objects and other toxins

• Never giving human medication without veterinary advice

• Investigating unexplained fever, anemia, or dark urine promptly

• Keeping an accurate medication, transfusion, illness, and vaccination history

• Creating an individualised vaccination plan after a previous immune-mediated disease

Onions, garlic, zinc, acetaminophen, and other substances may cause non-immune hemolysis rather than classic IMHA. Preventing these exposures remains important because the resulting anemia can be equally serious and may initially look similar.

There is no established diet or supplement that prevents IMHA.

Frequently Asked Questions

Can IMHA be cured?

Some animals achieve complete remission and eventually stop medication. Others require prolonged treatment, experience relapse, or need long-term low-dose medication. The response during the first weeks and the presence of complications strongly affect the outlook.

Is IMHA contagious?

IMHA itself is not contagious. However, an underlying infectious disease associated with hemolysis may be transmissible by ticks, fleas, blood exposure, or other routes depending on the organism.

Does every animal with IMHA need a blood transfusion?

No. Transfusion decisions are based on the severity and speed of the anemia together with evidence of inadequate oxygen delivery. Some patients remain stable without transfusion, while others require one or several transfusions.

Can a dog survive multiple blood transfusions?

Yes. Some dogs require repeated transfusions before immune destruction is controlled. Each transfusion requires careful blood typing, compatibility assessment, administration, and monitoring, but needing more than one transfusion does not automatically mean treatment will fail.

Can vaccines cause IMHA?

Current evidence shows a possible temporal association in a small proportion of dogs, but it does not prove causation. Vaccine history should be documented and future vaccination decisions individualised, particularly after a previous episode of IMHA. (OUP Academic)

The Most Important Takeaway

IMHA is a serious, rapidly changing disease that requires urgent veterinary care. The greatest immediate concerns are inadequate oxygen delivery from severe anemia and, particularly in dogs, life-threatening thrombosis.

A diagnosis should be based on a combination of findings rather than one blood smear feature or one Coombs result. Treatment commonly requires hospitalization, immunosuppression, careful transfusion decisions, clot prevention, investigation for underlying disease, and months of structured monitoring.

Many affected dogs and cats can survive, but early recognition and aggressive management give them the strongest chance.

---

If you are unsure whether your pet’s signs are urgent, or need help understanding IMHA blood results and the recovery plan, ASK A VET™ can provide additional guidance alongside your treating veterinarian.